Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 02, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general financial performance.
Material Changes
The filing details an increase in the notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan following a re-valuation of the cash element. The transaction occurred on October 31, 2007, at a price of $51.25 per ADR share. The specific increases for notified individuals are as follows:
- Dr R G Greig: 89 shares
- Dr JP Garnier: 72 shares
- Mr D Stout: 37 shares
- Dr D Pulman: 15 shares
- Mr C Viehbacher: 5 shares
- Mr W Louv: 6 shares
- Mrs C Bruck Slaoui: 1 share
- Dr M Slaoui: 1 share
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific disclosure of the director transactions required by Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the impact of the $51.25 ADR price on the total notional value of the US Retirement Savings Plan.
- Confirm the total aggregate number of shares allocated to all directors and managers in this specific transaction.
- Check subsequent filings to ensure all required disclosures for these individuals were completed in accordance with Rule 12g3-2(b).